{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263520","form_type":"8-K","ticker":"WAT","cik":"0001000697","company_name":"WATERS CORP /DE/","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.444373+00:00","generated_at":"2026-05-17T00:30:47.200238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance","bullets":["Sales $800M, +8% as reported and constant currency, above guidance.","GAAP EPS $2.50; non-GAAP EPS $3.40, up 16% YoY, above guidance.","Pharma +11% cc; instruments +6%, recurring +9% cc; chemistry double-digit growth.","FY25 constant currency sales growth guidance raised to +6.7% to +7.3%; non-GAAP EPS raised to $13.05-$13.15.","Integration planning for BD Biosciences acquisition progressing; CEO confident in synergies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263520","json":"https://secwatch.observer/filing/0001193125-25-263520.json","markdown":"https://secwatch.observer/filing/0001193125-25-263520.md","text":"https://secwatch.observer/filing/0001193125-25-263520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000697/000119312525263520/0001193125-25-263520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000697/000119312525263520/d40092d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:30:47.200238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}